Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade

This study will evaluate efficacy and safety of anti-PD-1/PD-L1 antibodies combined with bevacizumab and metronomic cyclophosphamide in patients with metastatic non-small cell lung cancer (NSCLC) and cutaneous melanoma previously treated with immune checkpoint blockade (ICB). The hypotheses of this study are that a combination of ICB, cyclophosphamide, and bevacizumab prolongs progression-free survival and overall survival, and also increases rates of objective responses and disease control.

NCT Number	NCT07130032
Lead Sponsor	EuroCityClinic LLC Collaborators: First Pavlov State Medical University in St. Petersburg, Russia
Conditions	Metastatic Non-small Cell Lung Cancer (NSCLC), Metastatic Cutaneous Melanoma
Enrollment	90 participants
Start Date	2025-08-14
Primary Completion	2025-08-14 (estimated)
Study Completion	2027-12 (estimated)
Updated on ClinicalTrials.gov	2025-08-19